Conditions: Relapsed Hepatoblastoma; Refractory Hepatoblastoma
Intervention: Other: Biospecimen collection
Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting
Feeds
32370 items (32370 unread) in 74 feeds
Acinar Cell Carcinoma
(207 unread)
Acinic Cell Carcinoma
(132 unread)
Adenoid Cystic Carcinoma
(651 unread)
Adrenal Gland Cancer
(2654 unread)
Ampulla Of Vater
(519 unread)
Anal Cancer
(2522 unread)
Angiosarcoma
(707 unread)
Appendix Cancer
(641 unread)
Bile Duct Cancer
(3783 unread)
Brain and CNS
(4595 unread)
Carcinoid
(938 unread)
Endocrine/Neuroendocrine
(4611 unread)
Gall Bladder Cancer
(1636 unread)
Hemangioendothelioma
(761 unread)
Hepatoblastoma
(546 unread)
Pancreas
(305 unread)
Phyllodes
(153 unread)
PMP and Mucinous Tumors
(413 unread)
Rhabdomyosarcoma
(1195 unread)
Sarcoma
(5401 unread)
Trial - Hepatoblastoma (19 unread)
-
Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative
Posted: September 27th, 2022, 2:00pm GMT
-
Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy
Posted: April 11th, 2022, 2:00pm GMT
Conditions: Transitional Cell Tumor; Hepatoblastoma; Liver Cancer; Pediatric Solid Tumor; Pediatric Cancer
Intervention: Drug: PD-1 inhibitor
Sponsor: RenJi Hospital
Not yet recruiting -
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Posted: March 31st, 2022, 2:00pm GMT
Conditions: Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor; Melanoma; Hepatoblastoma; Hepatocellular Carcinoma; Neuroblastoma; Wilms Tumor
Interventions: Procedure: Cryoablation Therapy; Drug: Nivolumab; Drug: Ipilimumab
Sponsors: Children's National Research Institute; Bristol-Myers Squibb
Recruiting -
131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults
Posted: October 1st, 2021, 2:00pm GMT
Condition: Central Nervous System/Leptomeningeal Neoplasms
Intervention: Drug: 131I-omburtamab
Sponsors: Memorial Sloan Kettering Cancer Center; Y-mAbs Therapeutics, Inc
Available -
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Posted: May 25th, 2021, 2:00pm GMT
Conditions: Recurrent Solid Tumor; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Wilms Tumor; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma
Interventions: Drug: Onivyde; Drug: Talazoparib; Drug: Temozolomide
Sponsors: St. Jude Children's Research Hospital; Pfizer; Ipsen
Recruiting -
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Posted: May 21st, 2021, 2:00pm GMT
Conditions: Pediatric Solid Tumor; Osteosarcoma; Rhabdomyosarcoma; Neuroblastoma; Ewing Sarcoma; Wilms Tumor; Adrenocortical Cancer; Desmoplastic Small Round Cell Tumor; Germ Cell Cancer; Rhabdoid Tumor; Clear Cell Sarcoma; Hepatoblastoma; Melanoma; Carcinoma; Malignant Peripheral Nerve Sheath Tumors; Soft Tissue Sarcoma
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: MESNA; Drug: B7-H3 CAR T cells
Sponsor: St. Jude Children's Research Hospital
Recruiting -
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Posted: April 20th, 2021, 2:00pm GMT
Conditions: Colorectal Carcinoma; Endometrial Carcinoma; Melanoma; Neuroblastoma; Ovarian Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Desmoid Fibromatosis; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Refractory Desmoid Fibromatosis; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Hepatocellular Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Solid Pseudopapillary Neoplasm of the Pancreas; Wilms Tumor
Interventions: Procedure: Dual X-ray Absorptiometry; Drug: Tegavivint; Procedure: X-Ray Imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting -
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Posted: July 23rd, 2020, 2:00pm GMT
Conditions: Pediatric Solid Tumor; Germ Cell Tumor; Retinoblastoma; Hepatoblastoma; Wilms Tumor; Rhabdoid Tumor; Carcinoma; Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Synovial Sarcoma; Clear Cell Sarcoma; Malignant Peripheral Nerve Sheath Tumors; Desmoplastic Small Round Cell Tumor; Soft Tissue Sarcoma; Neuroblastoma; Melanoma
Interventions: Biological: second generation 4-1BBζ B7H3-EGFRt-DHFR; Biological: second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
Sponsor: Seattle Children's Hospital
Recruiting -
A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy
Posted: July 20th, 2020, 2:00pm GMT
Condition: Hepatoblastoma
Interventions: Drug: Sodium Thiosulfate Injection; Procedure: Primary surgery resection; Drug: mono CDDP-Group A2; Drug: Cisplatin, 5-Fluorouracil, Vincristine, Doxorubicin-Group C; Procedure: Biopsy; Procedure: Resection or transplant; Procedure: Resection of pulmonary nodules; Drug: mono CDDP- Group B; Drug: Block 1 to 3 (Cisplatin, Doxorubicin) Group D; Drug: Consolidation (Carboplatin, Doxorubicin) -Group D1; Drug: Consolidation (Carboplatin +Doxorubicin/Vincristine + Irinotecan)-Group D2
Sponsors: Shanghai Children's Medical Center; Children's Hospital of Fudan University; Shanghai Children's Hospital
Recruiting -
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
Posted: March 25th, 2020, 2:00pm GMT
Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Recurrent Langerhans Cell Histiocytosis; Recurrent Lymphoma; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent WHO Grade 2 Glioma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Histiocytic and Dendritic Cell Neoplasm; Refractory Langerhans Cell Histiocytosis; Refractory Lymphoma; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory WHO Grade 2 Glioma; Wilms Tumor
Intervention: Drug: Selpercatinib
Sponsors: National Cancer Institute (NCI); Children's Oncology Group
Recruiting -
Molecular Basis of Pediatric Liver Cancer
Posted: May 22nd, 2019, 2:00pm GMT
Conditions: Childhood Liver Cancer; Liver Malignant Tumors; Embryonal Sarcoma of Liver (Disorder); Hepatoblastoma; Hepatocellular Carcinoma; Rhabdoid Tumor of Liver
Intervention:
Sponsor: University of Pittsburgh
Recruiting -
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Posted: August 7th, 2018, 2:00pm GMT
Conditions: Pediatric Solid Tumor; Germ Cell Tumor; Retinoblastoma; Hepatoblastoma; Wilms Tumor; Rhabdoid Tumor; Carcinoma; Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Synovial Sarcoma; Clear Cell Sarcoma; Malignant Peripheral Nerve Sheath Tumors; Desmoplastic Small Round Cell Tumor; Soft Tissue Sarcoma; Neuroblastoma
Interventions: Biological: second generation 4-1BBζ EGFR806-EGFRt; Biological: second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
Sponsor: Seattle Children's Hospital
Recruiting -
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Posted: July 11th, 2017, 2:00pm GMT
Conditions: Malignant Solid Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent WHO Grade 2 Glioma; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Wilms Tumor
Interventions: Drug: Ensartinib; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group
Recruiting -
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Posted: July 11th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Malignant Glioma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Rhabdoid Tumor; Stage III Osteosarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; Wilms Tumor
Interventions: Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Samotolisib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Posted: July 7th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Low Grade Glioma; Malignant Glioma; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Primary Central Nervous System Neoplasm; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Rhabdoid Tumor; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Wilms Tumor
Interventions: Drug: Erdafitinib; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Sponsor: National Cancer Institute (NCI)
Recruiting -
Paediatric Hepatic International Tumour Trial
Posted: January 11th, 2017, 3:00pm GMT
Conditions: Hepatoblastoma; Carcinoma, Hepatocellular
Interventions: Drug: Cisplatin; Drug: Doxorubicin; Drug: Carboplatin; Drug: 5Fluorouracil; Drug: Vincristine; Drug: Etoposide; Drug: Irinotecan; Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Sorafenib
Sponsors: University of Birmingham; Fundació Institut Germans Trias i Pujol; University Hospital Munich; University Hospital, Bonn; University of Kiel; University Hospital Tuebingen; University of Padova; Ludwig-Maximilians - University of Munich; Medical University of Gdansk; Cliniques universitaires Saint-Luc- Université Catholique de Louvain; Motol University Hospital, Prague; Rennes University Hospital; Children's University Hospital, Ireland; University of Oslo; Princess Maxima Center for Pediatric Oncology; Andaluz Health Service; Swiss Pediatric Oncology Group; Gothia Forum - Center for Clinical Trial; St James's University Hospital, Leeds; Bambino Gesù Hospital and Research Institute; Newcastle University Centre for Cancer, Newcastle; Experimental Cancer Medicine Centres; XenTech, Evry
Recruiting -
Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience
Posted: September 23rd, 2015, 2:00pm GMT
Condition: Hepatoblastoma
Intervention:
Sponsor: Assiut University
Recruiting -
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Posted: March 5th, 2013, 3:00pm GMT
Condition: Refractory and/or Relapsed Metastatic Solid Tumors
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Radiation: low dose total body irradiation; Drug: Melphalan; Drug: Tacrolimus
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting -
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Posted: January 6th, 2012, 3:00pm GMT
Conditions: Ewing's Family Tumors; Renal Tumors; Hepatoblastoma; Rhabdomyosarcoma; Soft Tissue Sarcoma; Primary Malignant Brain Neoplasms; Retinoblastoma; Medulloblastoma; Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET); Atypical Teratoid/Rhabdoid Tumor (AT/RT); CNS Tumors; Germ Cell Tumors
Interventions: Drug: Ifosfamide; Drug: Etoposide; Drug: Mesna; Biological: G-CSF; Drug: Busulfan; Drug: Melphalan; Drug: Thiotepa; Biological: Autologous stem cell infusion; Radiation: Radiation; Drug: Carboplatin; Drug: Paclitaxel; Procedure: Leukapheresis; Drug: Anti-seizure prophylaxis; Drug: Ursodiol
Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting